Johannes Fruehauf MD PhD has been an advisor for biotechnology companies at various stages, spanning the range from inception and pre-funding to public companies. His expertise spans the design of preclinical and clinical studies as well as regulatory interaction, particularly with CBER. He is a frequent speaker on questions of biologics drug development and the author of a recent review discussing the development of live therapeutic agents. Dr. Fruehauf’s clinical areas of expertise include both Gastroenterology and Obstetrics/Gynecology.
